1、S, “ -、v“、 -Q h,B。 ID:1 . 0 = s10 s J . 2MD,1998,17(2):126.2 l, . o0 = s?hy J .6D Sv,1997,26(1):73-74.3 Y.0 = s?hEB _ J .D, 1994,16(2):85-87.4 1,b -. 0 = s?h1“ J . S,1993,28(3):147-149.5 g .0 = s o209 s J .D,1998,29(2):64-65.6 B.0Fh106 “5s J .)D ,10、i、 m 8 = 。C|CRF y s /。2.1 控制血磷水平 M ? , PJ F%V9 3,P
2、THV 3,V7 F?J G、 / ! 。h Y, e50mg L/。2.1.1 K J CRF* K 700900mg d。2.1.2 4 P 4 ,1 /+:2.1.2.1 _ h * P4,y V? 3 h, w、 、 h,C 。2.1.2.2 4 V, 6,PTHs , V hB。l65 H P,v65H P。4 、Z 。V , CRF H,Z M1rT D,4 ? e,OB。2.1.2.3 h、4 5,6 Sevelamerhydrochloride:c ?$ l 。Hervas7i PSevelamerZ 1 ,TA U (V P/, 6Sevelamer V ,#V ?CRFi
3、“m。 Rena-gel: V、 PTH(intactPTH,iPTH)、9%? %?,Y %? , P ,0 sz。2.1.2.4 、M、$5 ) 。2.1.3 i “ Qi HWiW 1,z e, i3Q, Q HW4h 。2.2 维生素D代谢产物的使用82.2.1 ? P2.2.1.1 P HWW X1 ? PWT, 。2.2.1.2 0o M , ?0og 。Slatopolsky4 ?r, 01 g。0 Vh f%, N。2.2.1.3 V?4 0.25 1.00g d, 4 2 4g, 2Q。; rT? E,J G X。2.2.2 ? P V , P25- 3 D3 650 nmo
4、l L , ?1000U ?X。4 v 3 468D ACTA ACADEMIAE MEDICINAE XUZHOU 2003,23(5)DB,、 /“# Pi - / ?0。h f%,S e/1 V10000U ?。2.2.3 E ?(1- 3 D3) 3 qh PY% P450 0V ?M。?4 0.50 2.00 g d。V “59 A,E ? ?。2.2.4 3 D3 2.2.4.1 22-oxacalcitriol V ? 。 Vh /vs M“ J F =PTH -mRNA,g V U PTH i。8 V 3 D C 10 。 7 S “54g L 22-oxacal-citrio
5、l r, “ - ? L22-oxacalcitriolr Z ?1- 3 D3 。2.2.4.2 Paracalcitol(19-nor-1-25- 3 D2) B、4Tv、4 L,Martin11,48%CPTH/30% ,7Paracalcitol68%PTH/30% 。 ?V1 Paracalcitol ?。2.2.5 Pi Y P 3 D W,A 1 21Q b、i。 T? 3, ViA i,c4。 T ? 3,yp J e,9F g44 , 4VB/; H4i q。2.3 甲状旁腺次全切除术122.3.1 M“ i1S8iPTH i,70 F、。 35: |、 h 、8 。 13
6、, B a。 M X4pJ F V1g, 3 D 6 8iPTH i / H, I nJ F M“ 。 iJ GCRF /M H。y /M,J F9 3 I。V , /M4% (37J F M“ 14 。2.3.2 m #Z T W% m V IS S 。 - J F Mvs M“ B T V |。J F M /M : /M G 3 D 。2.3.3 iPTH i/,C m。() m, MS b imf / ( 7 S y 10mg,20mg h)。E , W 。, 3 D3( ?E ?)。4 %。h , ? 6 g ?。 3 D4 Kvh ,i S ba (AP) i。YAP7 S9,AP/
7、 H, ? /, HBvv 6。2.4 甲状旁腺内钙三醇或乙醇注射2.4.1 Y? 2/J F =Y? 1992 MGiangrande4。 Y? V P9 3J FF,8 l,y7 ? 9。 Fletcher15NZErT V O rT J F M“,NZE X #。 4 Y? (PEIT)T , “ YVY?4 P9 3F8。2.4.2 ? V4J F = ? i79F ? , PTHs T 3 D3 .C。 VYVO% %( 5), P 1- 9,V7425- 3 D3_1,25-= 3 D3,h | 3 D3 。 B , V L “5 L。 ID:1 SzaboA, SchmutzA,
8、 PesianS, etal.RegulationofintestinalvitaminDreceptorexpression inexperimentaluraemia:effectsofparathyroidec-tomyandadministrationofPHT J .NephrolDialTransplant,1998,13(2):340-349.2 OlmosJM, MartinezJ, deFranciscoAL, etal.1,25-Dihydroxyvita-minD3 receptorsinperipheralbloodmonoclear cellsfrom patient
9、swithrenalinsufficiency J .Methods Find Exp Clin Pharmacol,1998, 20(8):699-707.3 PatelSR, KeHQ, VanholderR, etal.InhibitionofcalcitriolreceptorbindingtovitaminDresponseelementsbyuremictoxins J .JClinIn-vest,1995,96(1):50-59.4 BrownAJ, Ritter CS, Finch JL, etal.Decreased calcium-sensingreceptorexpres
10、sion in hyperplastic parathyroid glands ofuremicrats:roleofdietaryphosphate J .KidneyInt,1999,55(4):1284-1292. 5 Malluche HH, Mawad H.Management of hyperphosphataemia ofchronickidney disease:lessons from the past and future directionsJ .NephrolDialTransplant,2002,17(7):1170-1175.6 Ramsdell R.Renagel
11、:a new and different phosphate binder J .ANNAJ,1999,26(3):346-347.7 Hervas JG, PradosD, CerezoS.Treatmentofhyperphosphatemiawithsevelamer hydrochloride in hemodialysis patients:A comparison withcalciumacetateJ .KidneyIntSuppl,2003,(85):69-72.8 SchomigM, Ritz E.Managementofdisturbed calciummetabolism
12、 inuraemicpatient:1.Use of vitamin Dmetabolites J .Nephrol DialTransplant,2000,15(Suppl5):18-24.9 Frazao JM, Chesney RW, Coburn JW.Intermittent oral 1alpha -hydroxyvitamin D2iseffectiveandsafeforthesuppressionofsecondaryhyperparathyroidismin haemodialysis patients.1alphaD2StudyGroup J .NephrolDialTr
13、ansplant,1998,13(Suppl3):68-72. 10 Halstead LR, WeinsteinRS, ChengSL, etal.Comparison of22-oxacalcitrioland 1,25-(OH)2D3onbonemetaboism inyoungX-linkedhypophosphatemicmalemice J .Am J Physiol,1996,270(1Pt1):E141-E147. 11 MartinKJ, GonzalezEA, GellensM, etal.19-nor-1-25-di-hydroxyvitaminD2(paricalcit
14、ol)safelyandeffectivelyreducesthelev-elsofintact parathyroid hormone in patients on hemodialysis J .JAm SocNephrol,1998,9(8):1427-1432. 12 SchomigM, Ritz E.Managementofdisturbed calciummetabolism inuraemicpatients:2.Indication for parathyroidectomy J .NephrolDialTransplant,2000,15(Suppl5):25-29. 13
15、BudisavljevicMN, CheekD, PlothDW.Calciphylaxisinchronicre-nalfailure J .JAmSocNephrol,1996,7(7):978-982.14 Schmid T, Muller P, Spelsberg F.Parathyroidectomy after renaltransplantation:aretrospectiveanalysis of long-termoutcome J .NephrolDialTransplant,1997,12(11):2393-2396. 15 FletcherS, Kanagasunda
16、ramNS, RaynerHC, et al.Assessmentofultrasound guided percutaneous ethanolinjection and parathyroidec-tomyinpatients with tertiary hyperparathyroidism J .NephrolDialTransplant,1998,13(12):3111-3117. 16 SchomigM, Ritz E.Managementofdisturbed calciummetabolism inuraemic patients:3.Potential perspective
17、s -calcimimetics J .NephrolDialTransplant,2000,15(Suppl5):30-31. 17 WadaM, FuruyaY, SakiyamaJ, etal.ThecalcimimeticcompoundNPSR-568 suppresses parathyroidcellproliferationinratswith re-nalinsufficiency.Controlofparathyroid cellgrowthviaacalcium re-ceptor J .JClin Invest,1997,100(12):2977-2983. 18 Wa
18、daM, IshiiH, FuruyaY, etal.NPS R-568haltsorreversesosteitisfibrosain uremic rats J .Kidney Int, 1998, 53(2):448-453. 19 UrenaP, FrazaoJM.Calcimimetic agents:Review and perspectives J .Kidney IntSuppl,2003,(85):91-96. 20 MonkawaT, Yoshida T, HayashiM, et al.Identification of 25-hydroxyvitaminD31alpha
19、-hydroxylasegeneexpression in macroph-ages J .KidneyInt,2000,58(2):559-568.l :2003-07-22 :2003-08-26I : ?S PE9 9 LS1984 M2 SE9 ,i|V U,9 |1987 MDI I E9 D B 。i | V P, mgkg-1-1;|V UM“|L ?1H, V TV U, mg kg dmgkg-1d-1V U。; (D)9“ ;(A)” ,D|83。 ,5 E9 ,7 , 10 kPa(75mmHg); B9 QC, V nQC H “ , E9 。 80 i 8 _B“,L,mldl。470D ACTA ACADEMIAE MEDICINAE XUZHOU 2003,23(5)
